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Abstract The PTEN gene (phosphatase and tensin homologous
on chromosome 10) is frequently mutated or deleted in a number
of malignancies including human hepatocellular carcinoma
(HCC). We reported previously that the hepatitis B virus X
(HBx) protein, known to be a causative agent in the formation
of HCC, activates insulin-like growth factor II (IGF-II) expres-
sion through Sp1 phosphorylation by protein kinase C (PKC) or
mitogen-activated protein kinase (MAPK) signaling. In this re-
port we demonstrate that the PTEN e¡ect on HBx induced
IGF-II activation in a hepatoma cell line. Expression of
PTEN and IGF-II was inversely related in di¡erent hepatoma
cell lines. PTEN expression induced decreased Sp1 DNA bind-
ing by dephosphorylating Sp1 and interfered with transcription-
al transactivation of IGF-II by HBx in hepatoma cells. The
protein phosphatase activity was involved in PTEN downregu-
lation of IGF-II transcription through downregulation of
MAPK, MAPK kinase phosphorylation and PKC translocation.
Our data suggest that PTEN blocks Sp1 phosphorylation in
response to HBx, by inactivating PKC, MAPK and MAPK
kinase which eventually downregulate IGF-II expression, during
the formation of HCC.
3 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
PTEN (phosphatase and tensin homologous on chromo-
some 10, also called MMAC1 or TEP1) is a recently cloned
tumor suppressor gene [1], which has dual speci¢city, dephos-
phorylating both lipid [2] and protein substrates [3]. The loss
of PTEN expression has been detected in many cancers, in-
cluding glioblastomas, breast and prostate carcinomas and
several syndromes with multiple tumor incidence [4]. In addi-
tion, germ-line mutations in the PTEN gene have been asso-
ciated with Cowden syndrome and related diseases in which
patients su¡er from a signi¢cantly increased risk of certain
tumors, including breast and thyroid cancers [5,6]. In further
support of the involvement of human PTEN mutations in
tumorigenesis, mice that are heterozygous for a PTEN dele-
tion also display frequent hyperplastic/dysplastic changes in
numerous tissues [7]. PTEN encodes a dual-speci¢city phos-
phatase that recognizes lipid substrate, the phosphatidylinosi-
tol 3-kinase (PI3K) products PI-3,4P2 and PI-3,4,5P3 (PIP3)
and protein substrates. It can dephosphorylate tyrosine-, ser-
ine- and threonine-phosphorylated peptides in vitro [3,8]. A
number of studies have also clearly demonstrated that PTEN
is a phosphatidylinositol 3-phosphatase and dephosphorylates
PIP3, a product of PI3K, which is required for the phosphor-
ylation and activation of protein kinase (PK) B/Akt [9], a
survival factor that protects various cell types against apopto-
sis. Consistent with the role of PTEN in the PI3K/Akt signal-
ing pathway, several lines of evidence suggest that PTEN
negatively regulates cell survival [10,11]. Several proteins in-
cluding Akt, PKA and PKC, which phosphorylate and acti-
vate p70S6k, as well as mitogen-activated protein kinase
(MAPK) kinase (MEK)/MAPK could potentially transduce
mitogenic signals mediated by PI3K, but so far, Akt is the
only one that has been found to be a¡ected by PTEN [12,13].
We recently demonstrated that transient or stable transfection
of the hepatoma cell line HepG2 with a hepatitis B virus X
protein (HBx) expression vector resulted in an increase in
insulin-like growth factor II (IGF-II) expression [14]. Elevated
levels of IGF-II expression were shown to play a role in the
neoplastic transformation of various cell types and were also
found in hepatocellular carcinomas, indicating that autocrine
production of IGF-II may also play a role in the deregulation
of hepatic cell proliferation [14]. In our previous work, we
also reported that HBx transactivates the IGF-II p4 promoter
through the two Sp1 binding sites by PKC- and MAPK-medi-
ated Sp1 phosphorylation, resulting in increased binding of
the phosphorylated form of Sp1 to its target DNA [15]. In
this study, we demonstrate that the protein phosphatase ac-
tivity of PTEN is involved in Sp1 dephosphorylation by
MAPK, MEK and PKC inactivation which is eventually in-
volved in downregulation of IGF-II expression in hepatoma
cell lines.
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2. Materials and methods
2.1. Cell culture and plasmids
HepG2 cells were grown and maintained in a humidi¢ed 5% CO2/
95% air atmosphere in Dulbecco’s modi¢ed Eagle’s medium supple-
mented with 10% heat-inactivated fetal bovine serum (JBI, Daegu,
Korea) and 1% penicillin/streptomycin solution. Antibiotics and cul-
ture media were obtained from JBI. Schneider line 2 (SL2) cells were
maintained in Schneider Drosophila medium supplemented with 10%
heat-inactivated fetal bovine serum and 1% penicillin/streptomycin
solution. SL2 cells were grown and maintained at 22‡C. The HBx
expression vector for eukaryotic cell expression was constructed using
pMAMneo (Clontech, Palo Alto, CA, USA) by inserting full-length
HBx cDNA. The PTEN wild type (wt) and mutant eukaryotic expres-
sion vectors (PTEN C124S, PTEN G129E) under the control of cy-
tomegalovirus promoter were a kind gift from Dr. Ji Sung Kil, Kyung
Hee University, Seoul, Korea.
2.2. Transient transfection and CAT assay
DNA transfection was carried out using the calcium phosphate
precipitation method. The cells were transiently transfected with a
plasmid construct (pIG0) containing 540 bp of the fourth promoter
region of the human IGF-II gene ligated upstream of the CAT re-
porter in pGEM [14]. After 16 h, the cells were washed with phos-
phate-bu¡ered saline (PBS) and fed again with fresh serum-containing
medium, then the plates were incubated for an additional 48 h. The
cells were then harvested and extracts were assayed for CAT activity
according to Gorman et al.’s method [16].
2.3. RNA extraction and Northern blot analysis
Total cellular RNA was extracted with Trizol (Life Technologies,
Grand Island, NY, USA) according to the procedure of Chomczinski
and Sacchi [17]. The RNA (15 Wg) was denatured in 5% formaldehyde
and electrophoresed on 1% agarose gels and transferred to Hybond-
Nþ nylon membranes (Amersham Pharmacia, Piscataway, NJ, USA).
Hybridization was carried out following the established protocol using
a radiolabeled 600 bp EcoRI/PstI fragment of the human IGF-II gene
[14].
2.4. Nuclear extract preparation and electrophoretic mobility shift
assay (EMSA)
Nuclear extracts (5 Wg) from cells were prepared and analyzed by
EMSA as previously described [15]. DNA binding reactions were
carried out in binding reaction mixture containing a 32P-labeled dou-
ble-stranded oligonucleotide probe corresponding to the Sp1 consen-
sus sequence at 22‡C then resolved on a 4% non-denaturing polyac-
rylamide gel.
2.5. Schneider cell transfection and in vivo phosphorylation of Sp1
SL2 cells were plated onto 100 mm plastic Petri dishes at a density
of 107 cells per plate 20^24 h before transfection. The cells were
transfected with a Sp1 expression vector (pSp1) and PTEN expression
vector (pPTEN) or HBx expression vector (pMAM-HX) using the
calcium phosphate precipitation method. The transfected cell cultures
were left undisturbed for 48 h before harvesting. In vivo phosphory-
lation and immunoprecipitations were performed as described by Lee
et al. [18]. For the binding reaction, cell extracts were adjusted to
250 mM NaCl using TENT bu¡er (5 mM Tris^HCl (pH 7.5), 5 mM
EDTA (pH 8.0), 100 mM NaCl, 1% (v/v) Triton X-100) containing
100 mM NaCl. 32P-labeled Sp1 was then immunoprecipitated with
polyclonal Sp1 antibody conjugated with agarose (Santa Cruz Bio-
technology, Santa Cruz, CA, USA), resolved on 8% sodium dodecyl
sulfate^polyacrylamide gel electrophoresis (SDS^PAGE) and autora-
diographed.
2.6. Protein extraction and immunoblotting
Protein extraction and immunoblotting were performed precisely as
described [15]. The anti-PTEN monoclonal antibody 6H2W1, which
was raised against the C-terminus of the PTEN [18], and polyclonal
anti-MAPK, anti-phospho-MAPK and anti-PKCK (New England
Biolabs, Hercules, CA, USA) were used at a 1:1000 dilution. Poly-
clonal anti-MEK, anti-phospho-MEK and IGF-II were purchased
from Santa Cruz and used at a 1:1000 dilution. Anti-actin antibody
(Sigma, St. Louis, MO, USA) was used at a 1:250 dilution as an
internal control.
2.7. PKC translocation assay
HepG2 cells (5U106) were transiently transfected with pCMV,
PTEN wt, C124S, G129E and HBx expression vectors using the cal-
cium phosphate method. The transfected cells were harvested and
washed three times with PBS, and their extracts were prepared. The
cells were resuspended in 500 Wl of bu¡er A (20 mM Tris^HCl (pH
7.5), 0.5 mM EGTA, 2 mM EDTA, 2 mM phenylmethylsulfonyl
£uoride, 10 Wg/ml of leupeptin, 10 Wg/ml of aprotinin), sonicated by
seven brief bursts with a Branson soni¢er with a microtip setting of 1,
and centrifuged at 100 000Ug for 1 h at 4‡C. The supernatant and
pellet, corresponding to the soluble cytoplasmic fraction and insoluble
particulate membrane fraction, respectively, were adjusted to 1% SDS
and 2% L-mercaptoethanol. The extracts were analyzed by Western
blot with rabbit anti-PKCK (New England Biolabs).
3. Results
3.1. PTEN suppresses IGF-II expression
To analyze PTEN expression in di¡erent hepatoma cell
lines, we examined the expression of the PTEN protein by
Western blotting. Fig. 1A shows that the abundance of
PTEN varied among di¡erent cell lines, with HepG2 and
PLC/PRF/5 having relatively low levels of the PTEN protein.
Since PTEN has been characterized as a tumor suppressor
Fig. 1. PTEN suppresses IGF-II expression. A: Expression of
PTEN and IGF-II in di¡erent hepatoma cell lines. The levels of
PTEN and IGF-II protein in Chang liver, HepG2, Hep3B, PLC/
PRF/5 and Huh 7 cells were determined by Western blot analysis
(4 Wg/lane) using an anti-PTEN monoclonal antibody and a poly-
clonal IGF-II antibody. An anti-actin antibody was used as an in-
ternal control. B: PTEN downregulated the expression of IGF-II
mRNA and protein. The levels of IGF-II mRNA and protein in
HepG2 cells were determined by Northern blotting (10 Wg/lane) and
Western blot analysis (4 Wg/lane). The amounts of PTEN were de-
termined in control (pCMV) and PTEN-transfected HepG2 cells by
Western blot analysis. C: Dose dependence of PTEN on transcrip-
tional repression of IGF-II p4 promoter. IGF-IIp4-CAT was co-
transfected into HepG2 cells with either a control vector (pCMV)
or varying concentrations of a PTEN expression vector (pPTEN).
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and elevated levels of IGF-II are present in a variety of hu-
man tumors where it functions as an autocrine or paracrine
growth stimulator, we ¢rst analyzed PTEN protein levels
against the level of IGF-II in a panel of hepatoma cell lines
by Western blotting. Interestingly, the levels of IGF-II were
inversely correlated with those of PTEN (Fig. 1A). HepG2
had the highest levels of IGF-II in accordance with its lowest
PTEN levels. To further investigate whether PTEN inhibits
IGF-II expression in HepG2 cells, we overexpressed PTEN
and examined the status of IGF-II expression. Transcripts
derived from promoter 3 (6.0 kb) and promoter 4 (4.8 kb)
were detected. The transiently PTEN-expressing HepG2 cell
line showed a decrease in the expression of IGF-II transcripts
(Fig. 1B). These results show that PTEN downregulates the
IGF-II transcript from promoters 3 and 4. Western blot anal-
ysis using an IGF-II antibody revealed that the protein levels
of IGF-II correlated with the abundance of mRNA in PTEN-
expressing HepG2 cells (Fig. 1B). To examine the downregu-
lation of IGF-II by PTEN on the IGF-II promoter 4 in these
cells, 10 Wg of the wt IGF-II promoter^CAT construct (pIG0)
was co-transfected with 5 Wg of the control expression vector
or a human PTEN expression vector into HepG2 cells (Fig.
1C). The CAT activity was diminished by PTEN in a concen-
tration-dependent manner in PTEN-transfected HepG2 cells.
These results show that PTEN downregulates the IGF-II tran-
scription in the hepatoma cell line, resulting in the downregu-
lation of the mRNA transcript and the expression of this
protein.
3.2. Mapping of the PTEN-responsive element in the p4
promoter of IGF-II
To determine the PTEN-responsive element sequences in
promoter 4 of IGF-II, 5P deletions of the promoter were con-
structed. The plasmids were co-transfected with either a con-
trol (pCMV) or the human PTEN expression vector (pPTEN)
into HepG2 cells. The levels of CAT activity were determined
48 h after transfection. The activities of constructs pIG0
(3411), pIG1 (3311), pIG2 (3213), pIG5 (3111), pIG7
(358), pIG8 (336), pIG9 (322) showed a 9.8-, 8.3-, 10.3-,
7.8-, 8.5-, 1.1- and 1.1-fold decrease, respectively, by PTEN
(Fig. 2A). Since the sequences between 358 and 336, which
showed PTEN responsiveness to the IGF-II p4 promoter,
contain two Sp1 binding sites, we investigated the importance
of these binding sites for PTEN activity. To examine the role
of the Sp1 binding sites in PTEN-mediated transcriptional
regulation, both Sp1 binding sites were inactivated by chang-
ing the three internal base pairs of each site (Fig. 2Ba, m3).
Since both of the Sp1 binding sequences (GGGTGG) showed
variations of the Sp1 consensus binding sequences
(GGGCGG), a single T (m1, m2) and both Ts (m4) of the
variant Sp1 sites were changed into C, in order to test the
ability of the Sp1 consensus binding (GGGCGG) sequences
to confer PTEN-mediated transcriptional regulation (Fig.
2Ba).
The e¡ect of PTEN on the Sp1 binding site mutant was
examined by co-transfection of the plasmid into HepG2 cells
with and without a PTEN expression vector (Fig. 2Bb). Wt
and mutant construct m1, m2, and m4 activities were de-
creased 9.8-, 8.2-, 8.3- and 6.8-fold, respectively, by PTEN,
whereas m3 was decreased only 1.1-fold. Thus, the change of
GGGTGG to the consensus Sp1 binding site GGGCGG had
no e¡ect on the ability of Sp1 to activate transcription, where-
as inactivation of both Sp1 sites abolished Sp1 activation.
These results suggest that PTEN can downregulate transcrip-
tion of the IGF-II p4 promoter through the Sp1 binding sites.
The GGGTGG Sp1 binding sites in the IGF-II p4 promoter
and the consensus Sp1 binding site GGGCGG conferred
equal responsiveness to PTEN.
Fig. 2. PTEN downregulates IGF-II transcription through Sp1 sites. A: Mapping of the PTEN-responsive element in the p4 promoter of the
IGF-II gene. The diagram shows the p4 promoter of IGF-II (3411^+124) fused to the CAT gene and the 5P deletion mutants (pIG1, 3311^
+124; pIG2, 3213^+124; pIG5, 3111^+124, pIG6, 372^+124; pIG7, 358^+124; pIG8, 336^+124; pIG9, 322^+124). The di¡erent IGF-II^
CAT plasmids were co-transfected into HepG2 cells with either a control vector (pCMV) or a PTEN expression vector (pPTEN). B: Evidence
that PTEN regulates IGF-II expression through the two Sp1 binding sites. a: Diagram of the mutations introduced into the two Sp1 binding
sites (GGGTGG) contained within construct pIG7. The T in either the 5P or 3P Sp1 binding site or both sites was changed to C in m1, m2,
and m4, respectively. Both Sp1 binding sites were mutated by inserting three base changes in each Sp1 binding site in mutant m3. b: E¡ect of
PTEN on transcription of the Sp1 binding site mutant and wt in HepG2. The parental plasmid pIG7 and the four mutants were co-transfected
into HepG2 cells with either a control vector (pCMV) or a PTEN expression vector (pPTEN).
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3.3. Decrease of DNA binding of Sp1 and in vivo
phosphorylation of Sp1 by PTEN
Modulation of Sp1-directed transcription by PTEN is a
complex phenomenon which depends on the signals that mod-
ulate the intrinsic transcriptional activity or the DNA binding
activity of the transcription factor Sp1. We tested the ability
of PTEN to modulate the Sp1 DNA binding activity. The
nuclear extracts from control (pCMV) and PTEN-expressing
HepG2 cells were checked for binding activity to Sp1 consen-
sus sequences of IGF-II promoter 4 (Fig. 3A). The Sp1 probe
binding activity of nuclear extracts from HepG2 cells trans-
fected with PTEN (Fig. 3A, lanes 4^6 and 10^12) was com-
pared to that of control vector-transfected HepG2 cells (Fig.
3A, lanes 1^3 and 7^9). In transiently PTEN-transfected
HepG2 cells, the Sp1 binding to its consensus DNA probe
decreased compared to the control vector-transfected HepG2
cells (Fig. 3A, lanes 4 and 10). In the presence of an Sp1
antibody, the slowest migrating complex is supershifted in
all cell lines (Fig. 3A, lanes 2 and 5). To determine if any of
the retarded bands shown in Fig. 3A represent Sp3 as well as
Sp1, gel shift analyses were performed in the presence of a
speci¢c anti-Sp3 antibody. When the anti-Sp3 antibody was
present in the binding reaction, the slowest migrating complex
was unaltered whereas the other two complexes were shifted
(Fig. 3A, lanes 3 and 6). These results demonstrate that Sp1
and Sp3 can both bind to the Sp1 consensus sequence in the
IGF-II promoter. Competition experiments with increased
amounts of unlabelled Sp1 oligonucleotide showed a gradual
decrease of the retarded bands including the Sp1 band (Fig.
3A, lanes 8, 9, 11 and 12). These results suggest that a com-
mon set of nuclear factors can interact with the Sp1 consensus
sequence within IGF-II promoter 4. Since PTEN inhibits Sp1
binding to Sp1 consensus sequences in HepG2 cells, we inves-
tigated whether PTEN a¡ected Sp1 phosphorylation, which
might be a cause of the decrease of Sp1 binding to its con-
sensus DNA sequences. Schneider cells which lack Sp1 were
transfected with a Sp1 expression vector (pSp1) and a PTEN
expression vector (pPTEN) and in vivo labeled with
[32P]ortho-phosphate. The cells were lysed, nuclear extracts
were prepared and Sp1 was precipitated with a Sp1 antibody.
After running on an 8% SDS^PAGE gel, the gel was auto-
radiographed. The results in Fig. 3B show that PTEN dephos-
phorylates Sp1 (lane 1) while nuclear extracts of Schneider
cells which were transfected with pSp1 showed basal levels
of the phosphorylated band (lane 2). These results showed
that the PTEN protein induces dephosphorylation of Sp1, in
vivo. In order to check whether a decrease in the amount of
Sp1 occurred in PTEN-expressing HepG2 cells, immunoblot-
ting experiments using nuclear extracts and Sp1 polyclonal
antibodies were done (Fig. 3B). No di¡erence in the amounts
of Sp1 in the extracts obtained from the two di¡erent cell lines
was detected. Thus, at least under our experimental condi-
tions, PTEN does not decrease the actual amount of Sp1 in
the cells. These results con¢rm that in the presence of a sim-
ilar amount of Sp1, PTEN induces posttranscriptional mod-
i¢cations that render the Sp1 complex less e⁄cient in its DNA
binding ability.
3.4. Inverse relationship of PTEN and HBx in IGF-II promoter
activation
We have previously shown that HBx transactivates IGF-II
promoter 4 through two Sp1 binding sites in HepG2 cells
[14,15]. To examine whether PTEN has an e¡ect on HBx
transactivation, HBx and PTEN were transiently coexpressed
in HepG2 cells and the transactivating activities of HBx and
PTEN on the IGF-II p4 promoter were examined using the
CAT assay. As shown in Fig. 4, HBx restores the PTEN-
induced decrease in the IGF-II promoter activity in a dose-
dependent manner (Fig. 4A), while the HBx transactivation
activity on the IGF-II p4 promoter was repressed by PTEN in
a dose-dependent manner (Fig. 4B). These results suggest that
HBx has a functional inverse relationship in vivo with the
PTEN function and might have an e¡ect on the IGF-II p4
promoter through the same pathway.
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Fig. 3. Decrease of DNA binding and in vivo phosphorylation of
Sp1 by PTEN. A: Decrease of Sp1 binding to the Sp1 consensus se-
quence by PTEN. Nuclear extracts obtained from pCMV (control)
and pPTEN-transfected HepG2 cells were preincubated at 37‡C
with a Sp1 consensus sequence DNA probe and were tested for Sp1
binding activity in a gel retardation assay. One Wg of a Sp1 and
Sp3 antibody was used for supershift gel retardation experiments
(lanes 2, 3, 5 and 6). Increasing amounts of cold Sp1 probe were
used for the competition experiment using pCMV or pPTEN cell-
transfected nuclear extracts (lanes 8, 9, 11 and 12). B: PTEN down-
regulates Sp1 phosphorylation. pSp1-transfected (lane 2) or pSp1,
pPTEN double-transfected (lane 1) Schneider cells were incubated
with 1 mCi/ml [32P]ortho-phosphate in phosphate-free medium for
1 h. After harvesting, the collected cells were lysed with IP bu¡er
and the radiolabeled Sp1 was immunoprecipitated with a polyclonal
Sp1 antibody (Santa Cruz) and resolved by 8% SDS^PAGE. Phos-
phorylated Sp1 is indicated by (P)Sp1. As a control, immunoblot-
ting was performed with a polyclonal antibody raised against re-
combinant Sp1. Each lane contains 20 Wg of protein (Sp1).
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3.5. The protein phosphatase activity is involved in PTEN
downregulation of IGF-II signaling
Having shown that the overexpression of PTEN downregu-
lates IGF-II expression in hepatoma cell lines, we next inves-
tigated whether inhibition of IGF-II expression was due to
either the protein or phospholipid phosphatase activity of
PTEN. For this purpose, we compared the e¡ect of wt
PTEN, G129E mutant PTEN and C124S mutant PTEN on
the activity of the IGF-II p4 promoter. The C124S mutation
results in a phosphatase-dead protein, with neither lipid nor
protein phosphatase activity. The G129E mutation results in
only a loss of lipid phosphatase activity with retention of
protein phosphatase activity. If the downregulation of IGF-
II expression in PTEN-expressing HepG2 cells is only medi-
ated through its lipid phosphatase activity, which is known to
counter the PI3K signaling pathway, one would expect that
the G129E mutant might have a similar e¡ect on IGF-II ex-
pression to that of the C124S mutant. As shown in Fig. 5A,
the IGF-II p4 promoter activity was not modi¢ed in the cells
overexpressing the C124S mutant, but decreased in the cells
overexpressing wt PTEN and the G129E mutant, both of
which have intact protein phosphatase activity (Fig. 5A).
These results suggest that the protein phosphatase rather
than the lipid phosphatase activity is important for downre-
gulation of IGF-II expression. We next investigated the ability
of PTEN in the regulation of the activities of MEK and
MAPK, which is known to be involved in the HBx-mediated
increase of IGF-II expression [15]. For this purpose, we ana-
lyzed the phosphorylation status of MEK or MAPK in a
hepatoma cell line expressing wt PTEN, C124S or G129E
mutant by Western blotting using antibodies which interact
speci¢cally with the phosphorylated form of MEK or MAPK
(Fig. 5B). Induction of wt PTEN or G129E in HepG2 cells
resulted in a reduction in the phosphorylation of MEK and
MAPK compared to controls (lanes 2 and 4). Conversely,
overexpression of the C124S lipid phosphatase-dead mutant
resulted in an increase of the phosphorylation of MEK and
MAPK compared to control cells. The reduction in the phos-
phorylation of MEK and MAPK caused by overexpression of
PTEN was not the result of a reduction in the absolute
amounts of the MEK or MAPK proteins (Fig. 5B). In addi-
tion, PTEN also decreases HBx-mediated phosphorylation of
MEK and MAPK in this cell line (Fig. 5B, lanes 5 and 6). We
next investigated the ability of PTEN, in the regulation of the
activity of PKC, which is also known to be involved in the
HBx-mediated increase in IGF-II expression [15]. For this
purpose, we examined the subcellular distribution of PKC in
hepatoma cell lines expressing wt PTEN, C124S or G129E
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Fig. 4. Inverse relation of PTEN and HBx in IGF-II promoter activation. A: PTEN interferes with the transactivation activity of HBx in
HepG2 cells. HepG2 cells were transiently co-transfected with 3 Wg of IGF-IIp4-CAT, 4 Wg of HBx expression vector (pMAM-HX) and 0, 0.2,
1.0, 2.0, and 3.0 of a PTEN expression vector (pPTEN) and analyzed for CAT activity. B: HBx restores the PTEN-induced decrease of IGF-II
promoter activity. HepG2 cells were transiently co-transfected with 3 Wg of IGF-IIp4-CAT, 4 Wg of a PTEN expression vector (pPTEN) and 0,
0.2, 1.0, 2.0, 3.0 and 4.0 Wg of pMAM-HX and analyzed for CAT activity.
p
C
M
V
P
T
E
N
 w
t
P
T
E
N
 C
1
2
4
S
P
T
E
N
 G
1
2
9
E
HepG2
1      2       3       4 
V
e
c
to
r
P
T
E
N
 w
t
P
T
E
N
 C
1
2
4
S
P
T
E
N
 G
1
2
9
E
H
B
x
H
B
x
+
P
T
E
N
 w
t
MAPK
MAPK
MEK
MEK
1        2       3       4       5     6
C M C M C M C M C M C M
p
C
M
V
P
T
E
N
 w
t
P
T
E
N
 C
1
2
4
S
P
T
E
N
 G
1
2
9
E
H
B
x
+
P
T
E
N
 w
t
H
B
x
PKCα
1      2      3      4       5       6       7       8       9  10     11     12
A B
C
p
p
Fig. 5. The protein phosphatase activity is involved in PTEN down-
regulation of IGF-II signaling. A: The e¡ect of wt and PTEN mu-
tants G129E and C124S on IGF-II transcription. HepG2 cells were
transiently co-transfected with 3 Wg of IGF-IIp4-CAT and 4 Wg of
PTEN wt, C124S, G129E expression vectors and analyzed for CAT
activity. PCMV vector-transfected HepG2 cells were used as a con-
trol. B: The e¡ect of wt and PTEN mutants G129E and C124S on
MEK and MAPK phosphorylation. 20 Wg protein of cell lysates
from pCMN, PTEN wt, C124S, G129E, HBx- and HBx+PTEN-
transfected cells were resolved on 8% SDS^PAGE and Western
blotted with polyclonal anti-MEK, anti-phospho-MEK, anti-MAPK
and anti-phospho-MAPK antibodies as indicated in Section 2.
C: The e¡ect of wt and PTEN mutants G129E and C124S on PKC
translocation. 20 Wg protein of cytosolic or membrane fractions
from pCMV, PTEN wt, C124S, G129E, HBx- and HBx+PTEN-
transfected cells were resolved on 8% SDS^PAGE and Western
blotted with a polyclonal anti-PKC antibody.
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mutants by Western blotting (Fig. 5C). Induction of the wt
PTEN and G129E mutant in HepG2 cells resulted in a de-
crease in membrane-bound PKC compared to controls (Fig.
5C, lanes 3, 4, 7 and 8). Conversely, overexpression of the
C124S phosphatase-dead mutant resulted in an increase in
membrane-bound PKC (Fig. 5C, lanes 5 and 6) compared
to the PTEN wt or G129E mutant. In addition, PTEN also
decreased HBx-mediated translocation of PKC in this cell line
(Fig. 5C, lanes 9^12).
4. Discussion
It is well established that HBx plays an essential role in
IGF-II activation during the formation of HCC [14,15].
Here, we demonstrate that overexpression of PTEN in hepa-
toma cells inhibits IGF-II expression and cell growth by
blocking MAPK, MEK and PKC activation in a PTEN pro-
tein phosphatase activity-dependent manner. Several lines of
evidence from this study also demonstrate that PTEN inhibits
the phosphorylation of Sp1, resulting in a decrease in Sp1
binding to the Sp1 consensus sequence in the IGF-II p4 pro-
moter. Overexpression of PTEN induced the dephosphoryla-
tion of MAPK and MEK and inhibited PKC translocation
which resulted in Sp1 transcription factor dephosphorylation.
Wt PTEN led to the suppression of IGF-II transcription,
MEK and MAPK phosphorylation and PKC translocation.
In contrast, expression of the phosphatase-dead mutant,
C124S, did not suppress IGF-II transcription, MEK and
MAPK phosphorylation and PKC translocation while the
G129E mutant, which showed a loss of lipid phosphatase
activity but retained the protein phosphatase activity, exerted
the same e¡ect as wt PTEN. Therefore, PTEN exerts an IGF-
II suppression e¡ect through its protein phosphatase activity.
Our results, in contrast to those of a recent report that shows
that both the protein and lipid phosphatase activities are in-
duced in PTEN-mediated growth suppression [19], indicate
that only the protein phosphatase activity is needed in IGF-
II inactivation. In their experiment, the lipid phosphatase
branch of PTEN upregulated p27 by blocking PI3K signaling,
whereas the protein phosphatase branch downregulated cyclin
D1, demonstrating bifurcation of PTEN’s lipid and protein
phosphatase signaling which ultimately converges at the G1/S
transition to block cell cycle progression [19]. A recent report
by Went et al. [20] demonstrated that PTEN blocks MAPK
phosphorylation in response to insulin stimulation by inhibit-
ing the phosphorylation of insulin receptor substrate (IRS)-1
and IRS-1/Grb2/SOS complex formation, which leads to
downregulation of cyclin D1, inhibition of cell cycle progres-
sion and suppression of cell growth. Although we assume that
the Akt signaling branch of PTEN is not involved in the
observed downstream e¡ect, based on the failure of the lipid
phosphatase PTEN mutant to exert the same e¡ect as the
protein phosphatase mutant at the transcriptional level, the
Akt phosphorylation status in HepG2 cells and subsequent
experiments on Akt signaling which might involve the activa-
tion of PTEN in downregulation of IGF-II expression need to
be veri¢ed. Our results together with previous results [14,15]
which describe IGF-II activation by PKC- and MAPK-depen-
dent Sp1 phosphorylation clearly demonstrate that PTEN
blocks Sp1 phosphorylation in response to HBx by inactivat-
ing PKC, MAPK and MEK which eventually downregulates
IGF-II expression thus inhibiting cell growth during the for-
mation of HCC.
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